Tutogen Medical, Inc. Announces Breakthrough In Treatment Of Cancerous Bone
PARSIPPANY, N.J., Nov. 24 /PRNewswire/ via NewsEdge Corporation -- Tutogen
Medical, Inc. (OTC Bulletin Board: TTGN) announced today the first
published case of successful removal of a malignant tumor from bone and the
subsequent reimplantation of that same bone following processing with the
company's proprietary Tutoplast(R) process of tissue preservation and viral
inactivation. The announcement follows the presentation of a case at the
annual meeting of the German-Austrian-Swiss Workgroup for tumors in the
maxillofacial area at the Justus-Liebig University in Giessen, Germany on
November 17.
"We are very excited with this breakthrough in the application of our
Tutoplast(R) process," said Karl H. Meister, Tutogen President and Chief
Executive Officer. "While the Tutoplast(R) process has been proven in the
processing of donor tissue, this new application confirms the tremendous
additional potential the process offers."
The case involved the removal of a malignant soft tissue tumor which had
infiltrated the jaw of the patient. The jawbone was partially removed and
treated with the Tutoplast(R) process, and successfully reimplanted 15
months ago with the cancer removed. This is the first published case of a
successful treatment of a bone outside the body and its subsequent
reimplantation. Standard treatment would have involved partial removal of
the jaw and replacement with bone from the patient's hip.
The procedure was performed by Professor Dr. J. Kreidler and Dr. T. Thien
of the University of Ulm, Germany.
Tutogen Medical, Inc. processes bioimplants for neurosurgical, orthopedic,
reconstructive and general surgical indications, utilizing its patented
Tutoplast(R) process of tissue preservation and viral inactivation. The
Company's Tutoplast(R) tissues are distributed worldwide through
subsidiaries in the U.S. and Germany, and through strategic alliances with
Mentor Corporation and IOP, Inc.
Certain statements in this news release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties, which may
differ materially from those set forth in these statements. In addition,
the economic, competitive, governmental, technological and other factors
identified in the Company's filings with the Securities and Exchange
Commission could affect such results.
SOURCE Tutogen Medical, Inc.
/CONTACT: George Lombardi, Chief Financial Officer, Tutogen Medical,
973-359-8444/ (TTGN)
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
